Redefining Triple-Negative Breast Cancer: Understanding the Clinical Evidence That Will Transform Practice
Source: Redefining Triple-Negative Breast Cancer: Understanding the Clinical Evidence That Will Transform Practice

Module

Sara Hurvitz, MD, FACP, provides her expert perspective on leveraging the latest clinical trial results for customized treatment of metastatic TNBC based on patient and disease characteristics.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Consider the key biologic features and different subtypes of TNBC to guide individualized therapy choices for patients with TNBC
  • Select optimal systemic therapy plans for patients with TNBC based on available clinical data and treatment guidelines
  • Manage treatment-related symptoms in patients with TNBC
  • Identify patients with TNBC who may be eligible for treatment with immune checkpoint inhibitors, including enrollment on clinical trials
  • Evaluate the therapeutic impact of enzalutamide in patients with androgen receptor–positive TNBC
  • Discuss emerging research, the mechanisms of action, and the role of targeted therapies for the management of patients with specific subtypes of TNBC

Topics covered include:

  • Redefining Triple-Negative Breast Cancer: Understanding the Clinical Evidence That Will Transform Practice
  • Current Chemotherapy Options for Optimal TNBC Treatment
  • PARP Inhibitors for Select Patients with mTNBC: BRCA1/2 Mutations
  • Immune Checkpoint Inhibitors for Patients With mTNBC
  • Other New Agents and Ongoing Clinical Trials: Androgen Receptor and PI3-Kinase Inhibitors
 

Faculty

  • Sara Hurvitz
    MD, FACP

Credit Information

  • Release Date:
    November 14, 2017
  • Expiration Date:
    November 13, 2018
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Sara Hurvitz, MD, FACP


Associate Professor of Medicine
Director,
Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Amgen, Bayer, BioMarin, Boehringer Ingelheim, Cascadian Therapeutics, Dignitana, Genentech, GlaxoSmithKline, Lilly, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, Puma Biotechnology, Roche, and Seattle Genetics.
 

Staff

Kristen M. Rosenthal, PhD


Managing Editor

Kristen Rosenthal, PhD, has no real or apparent conflicts of interest to report.
 

Kevin Obholz, PhD


Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
 

Megan Cartwright, PhD


Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
 

Gordon Kelley, 


Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
 

Jill Sakai, PhD


Editorial Contributor

Jill Sakai, PhD, has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for oncologists, registered nurses, and other specialty healthcare providers involved in the care of patients with breast cancer.


Goal

The goal of this activity is to improve the knowledge, understanding, and competence of participants at applying the available clinical evidence to individualize and optimize therapy and thereby improve outcomes for patients with triple-negative breast cancer.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Consider the key biologic features and different subtypes of TNBC to guide individualized therapy choices for patients with TNBC
  • Select optimal systemic therapy plans for patients with TNBC based on available clinical data and treatment guidelines
  • Manage treatment-related symptoms in patients with TNBC
  • Identify patients with TNBC who may be eligible for treatment with immune checkpoint inhibitors, including enrollment on clinical trials
  • Evaluate the therapeutic impact of enzalutamide in patients with androgen receptor–positive TNBC
  • Discuss emerging research, the mechanisms of action, and the role of targeted therapies for the management of patients with specific subtypes of TNBC
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by educational grants from Celgene Corporation, and Merck & Co., Inc..

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 14, 2017, through November 13, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.